Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women

Authors

  • Stephen E. Karp M.D.,

    1. Department of Surgery, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    2. Department of Oncology, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    3. Cancer Prevention Research Unit, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Current affiliation:
    1. Department of Surgery, Medical College of Virginia, Richmond, Virginia.
    Search for more papers by this author
  • Patricia N. Tonin Ph.D.,

    1. Division of Medical Genetics, Departments of Medicine and Human Genetics, Montreal General Hospital, McGill University, Montreal, Quebec, Canada
    Search for more papers by this author
  • Louis R. Bégin M.D.,

    1. Cancer Prevention Research Unit, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    2. Department of Pathology, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Search for more papers by this author
  • John J. Martinez Ph.D.,

    1. Department of Biotechnology, Corning-Nichols Institute, San Juan Capistrano, California
    Search for more papers by this author
  • Jian Chun Zhang M.D.,

    1. Department of Oncology, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Search for more papers by this author
  • Michael N. Pollak M.D.,

    1. Department of Oncology, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    2. Cancer Prevention Research Unit, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Search for more papers by this author
  • William D. Foulkes M.B., B.S., Ph.D.

    Corresponding author
    1. Cancer Prevention Research Unit, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    2. Division of Medical Genetics, Departments of Medicine and Human Genetics, Montreal General Hospital, McGill University, Montreal, Quebec, Canada
    • Cancer Prevention Research Unit, Room A-803, Sir Mortimer B Davis-Jewish General Hospital, 3755 Cote Ste Catherine, Montreal, Quebec, Canada H3T 1E2
    Search for more papers by this author

Abstract

BACKGROUND

In the Ashkenazim, three recurrent germline mutations have been identified in the breast carcinoma susceptibility genes BRCA1 and BRCA2: 185delAG, 5382insC (BRCA1), and 6174delT (BRCA2). The frequency of these mutations in the general Ashkenazi population approaches 2%. There is little available controlled data comparing the characteristics of breast carcinoma arising in BRCA1 mutation carriers or BRCA2 mutation carriers with that arising in noncarriers, although such data would be relevant to the urgent clinical need to develop risk-reduction strategies for individuals at increased risk due to genetic factors.

METHODS

The authors screened 149 unselected tumors arising in Ashkenazi Jewish women for the 185delAG, 5382insC, and 6174delT mutations and compared tumors arising in mutation carriers with tumors arising in noncarriers with respect to nuclear grade, steroid hormone receptor status, and axillary lymph node status.

RESULTS

In the 149 cases, the authors found 17 BRCA1 mutations (11.4%; 95% confidence interval [ci], 6.8-17.6%), and 4 6174delT BRCA2 mutations (2.7%; 95% CI, 0.8-6.7%). Tumors from women with BRCA1 mutations were significantly less likely to be estrogen receptor positive (age-adjusted odds ratio [or]: 0.091; P < 0.001) and more likely to have a high nuclear grade (OR: 5.55; P 0.001) than tumors in which no mutation was identified. All four BRCA2 positive breast carcinoma specimens were estrogen receptor positive.

CONCLUSIONS

Breast carcinoma arising in Ashkenazim BRCA1 mutation carriers has adverse prognostic features relative to those arising in noncarriers in the same population. This may be relevant to the development of prevention and treatment strategies for these women. For example, if tamoxifen reduces the risk of breast carcinoma via its antiestrogenic effects, it is possible that this effect will be diminished in the largely estrogen receptor negative BRCA1-related hereditary breast carcinoma. Cancer 1997; 80:435-41. © 1997 American Cancer Society.

Ancillary